Nine new medicines recommended for approval by EMA/CHMP, including four orphans

22 April 2017
ema_big

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended a total of nine new medicines for approval at its April meeting.

The CHMP recommended granting marketing authorisations for two orphan medicines to treat rare neurodegenerative conditions in children. The first, US biotech firm Biogen’s (Nasdaq: BIIB) Spinraza (nusinersen) is to treat patients with spinal muscular atrophy (SMA) It was under an accelerated assessment program. There is currently no approved therapy in the EU for the treatment of spinal muscular atrophy.

The second, from BioMarin Pharmaceuticals (Nasdaq: BMRN), is Brineura (cerliponase alfa) to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease. This was also reviewed under EMA’s accelerated assessment program. There are currently no medicines approved for treatment of CLN2 disease. Current options only treat the symptoms of the disease, a form of Batten disease, which is also known as tripeptidyl peptidase 1 (TPP1) deficiency.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical